Recommended Momentum ‘How’ and ‘Why’: Novartis (NYSE:NVS), Flamel Technologies (NASDAQ:FLML)

Shares of Novartis AG (NYSE:NVS) [Trend Analysis] runs in leading trade, it surging 1.01% to traded at $71.78. The firm has price volatility of 0.95% for a week and 1.07% for a month. Its beta stands at 0.68 times. Novartis (NVS) declared that contract for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. The financial details of the deal were not disclosed. Ziarco’s lead investigational product, ZPL389, is a potential first-in-class oral treatment for moderate-to-severe eczema.

VasantNarasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “We are proud of our dermatology capabilities shown by the recent successful launches of Cosentyx and Xolair. Now we’re excited about a potential new medicine for people with eczema through the acquisition of Ziarco and the addition of a first-in-class oral H(4) receptor antagonist to our growing pipeline.” Narrow down four to firm performance, its weekly performance was 5.13% and monthly performance was -1.17%. The stock price of NVS is moving up from its 20 days moving average with 3.35% and isolated negatively from 50 days moving average with -0.43%.

Flamel Technologies SA (NASDAQ:FLML) [Trend Analysis] luring active investment momentum, shares a loss -1.35% to $10.21. Flamel Technologies SA (NASDAQ:FLML) revealed that first patient has been dosed in its Rest-On Phase III clinical trial of FT218, a once-nightly formulation of sodium oxybate utilizing the Company’s proprietary Micropump technology, for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy.

Mike Anderson, Flamel’s Chief Executive Officer, remarked, “This is an exciting milestone for Flamel. FT218 is our most important asset and has the potential to provide a number of benefits to narcoleptic patients, who suffer from debilitating quality of life issues. We are seeing important interest in this trial from both physicians and patients alike, and are excited to continue the screening and enrollment process as more sites are initiated throughout Europe, Canada and the U.S.” The total volume of 152951 shares held in the session was surprisingly higher than its average volume of 112.58 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 138.00%, and looking further price to next year’s EPS is 104.30%. While take a short look on price to sales ratio, that was 2.84 and price to earning ratio of 33.17 attracting passive investors.

 

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *